Rechallenging trials in mice treated with PTT and anti-CTLA-4 after 90 days of tumor-free survival revealed long-term immune protection against tumor recurrence, swiftly eradicating the rechallenging tumor [140]. Here, CTLA4 is linked to neoplasm.